2026-11-07Regulatory: key points of the EMA synthetic peptide guideline (effective 1 June 2026)
Quickgene
Analytical CRO

Characterization of GLP-1 and related metabolic peptides

One sample set. Four complementary methods. One integrated report.

Choose from SV-AUC, circular dichroism, icIEF and cell-based potency assays to evaluate aggregation, structure, charge heterogeneity and biological activity.

Request a Technical AssessmentExplore Analytical Services
Analytical Services SV-AUC / CD / icIEF
Latest updates

What’s new at Quickgene

All updates
  1. New
    Application note

    Regulatory: key points of the EMA synthetic peptide guideline (effective 1 June 2026)

  2. New
    Application note

    Regulatory: synthetic peptide requirements compared — China CDE, US FDA and EU EMA

  3. New
    Application note

    Technical article — CD secondary structure: reference sets, concentration normalization and HT-voltage cut-offs

  4. New
    New product

    New product: CHO-GLP-1 luciferase reporter cell line (T82011) for GLP-1R potency testing

  5. New
    Application note

    Technical article — icIEF charge heterogeneity: pI calibration, focusing completeness and peak-area limits

  6. New
    New method

    Four new method pages: SV-AUC, circular dichroism, icIEF and cell-based bioassay

01 / Analytical services

Four methods to answer different questions

01

SV-AUC aggregation and self-association

What sedimenting species are present in solution? When would SV-AUC help investigate an SEC result?

02

Circular dichroism (CD)

Do spectral profiles differ between test and reference samples, or as temperature changes?

03

icIEF isoelectric point and charge heterogeneity

What is the pI and charge profile? Do the profiles differ across lots or formulations?

04

Cell-based bioactivity and relative potency

Does the sample activate the target receptor? How does its potency compare with a reference?

02 / Target molecules

Explore studies by molecule

Semaglutide

Fatty-acid side chain & self-association

Tirzepatide

39-mer dual GIP/GLP-1 agonist

Retatrutide

Triple-agonist peptide

Cagrilintide

Amylin analog, fibrillation-prone

Impurity Library

Peptide Impurity Reference Standards

Search reference standards for semaglutide, tirzepatide and retatrutide. Request a current availability and document check.

Explore the Impurity Library →
03 / How we work

From study question to report

  1. Describe your molecule and samples

    Provide the molecule name or code, sample format and the question you want to answer.

  2. Confirm the scope

    Agree on the method combination, sample requirements, deliverables and timeline.

  3. Receive your results

    Receive results for a single method or an integrated report, with agreed figures and method notes.

04 / Technology and quality

What to agree before sending samples

We confirm study conditions, deliverables and documentation requirements with your team.

Quality
  • Study scope and sample acceptance
  • Method suitability and reference materials
  • Data, figures and analysis notes
  • Applicable guidance and documentation, as agreed

Technical assessment

Discuss your molecule and study goals

Request an Assessment